Prevalence and risk factors for antibiotic-resistant community-associated bloodstream infections

抗生素耐药性社区获得性血流感染的流行情况和危险因素

阅读:1

Abstract

BACKGROUND: Antibiotic resistance is increasing in many community settings. The purpose of this study was to determine the proportion of antibiotic resistant community-associated bloodstream infections (CA-BSIs) present on hospital admissions to identify risk factors for acquiring resistant versus susceptible CA-BSIs and to describe the incidence of concurrent infections with CA-BSIs. METHODS: We conducted a retrospective cohort study of patients discharged from one community, one pediatric, and two tertiary/quaternary care hospitals within an academically affiliated network in the borough of Manhattan in New York, NY, from 2006 to 2008. The CA-BSIs present at hospital admission were defined as BSIs occurring within the first 48h of hospitalization. Infections and patient characteristics were identified using data available from patients' electronic medical records and discharge records. RESULTS: In total, 1677 CA-BSIs were identified. Staphylococcus aureus had the largest proportion of resistance (41.2%), followed by enterococcal species (24.3%), Pseudomonas aeruginosa (20.2%), Streptococcus pneumoniae (16.6%), Acinetobacter baumannii (10.0%), and Klebsiella pneumoniae (9.9%). Significant predictors of resistance were prior residence in a skilled nursing facility (OR, 2.55; 95% CI, 1.39-4.70), advanced age (1.01; 1.002-1.02), presence of malignancy (0.58; 0.37-0.91), prior hospitalization (1.62; 1.17-2.23), a weighted Charlson score (1.09; 1.02-1.17) for S. aureus, presence of malignancy (1.82; 1.004-3.30), prior hospitalizations (2.03; 1.12-3.38) for enterococcal species, and younger age for S. pneumoniae (p=0.02). Urinary tract infections were the most common concurrent infection (n=45/87, 51.7%). CONCLUSION: Over 27% of the CA-BSIs present on admission were antibiotic resistant. Understanding the prevalence and risk factors for CA-BSIs may help improve empiric antibiotic therapy and outcomes for patients with community-onset infections.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。